Advertisement
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Bacia JJSpyridakis LKBarsanti JA, et al. Ibuprofen toxicosis in a dog. J Am Vet Med Assoc 1986; 189:918–919.
-
2.
Poortinga EWHungerford LL. A case-control study of acute ibuprofen toxicity in dogs. Prev Vet Med 1998; 35:115–124.
-
3.
Elliott GAPurmalis AVanderMeer DA, et al. The propionic acids. Gastrointestinal toxicity in various species. Toxicol Pathol 1988; 16:245–250.
-
4.
Wooten JGBlikslager ATRyan KA, et al. Cyclooxygenase expression and prostanoid production in pyloric and duodenal mucosae in dogs after administration of nonsteroidal antiinflammatory drugs. Am J Vet Res 2008; 69:457–464.
-
5.
Surdyk KKSloan DLBrown SA. Evaluation of the renal effects of ibuprofen and carprofen in euvolemic and volume-depleted dogs. Intern J Appl Res Vet Med 2011; 9:129–136.
-
6.
Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971; 231:232–235.
-
7.
Brown SA. Renal effects of nonsteroidal anti-inflammatory drugs. In: Kirk RWBonagura JD, eds. Current veterinary therapy X. WB Saunders Co, 1989;1158–1161.
-
8.
Bergh MSBudsberg SC. The coxib NSAIDs: potential clinical and pharmacologic importance in veterinary medicine. J Vet Intern Med 2005; 19:633–643.
-
9.
Ricketts APLundy KMSeibel SB. Evaluation of selective inhibition of canine cyclooxygenase 1 and 2 by carprofen and other nonsteroidal anti-inflammatory drugs. Am J Vet Res 1998; 59:1441–1446.
-
10.
Boothe D. Anti-inflammatory drugs. In: Small animal clinical pharmacology and therapeutics. WB Saunders Co, 2001:281–311.
-
11.
Smith WLDeWitt DL. Biochemistry of prostaglandin endoperoxide H synthase-1 and synthase-2 and their differential susceptibility to nonsteroidal anti-inflammatory drugs. Semin Nephrol 1995; 15:179–194.
-
12.
Dvornik DLee DK. Theoretical mechanism for the gastrointestinal safety of etodolac: selective sparing of cytoprotective prostaglandins. Clin Rheumatol 1989; 8(suppl 1):16–24.
-
13.
Dvornik DM. Tissue selective inhibition of prostaglandin biosynthesis by etodolac. J Rheumatol Suppl 1997; 47:40–47.
-
14.
Streppa HKJones CJBudsberg SC. Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs in canine blood. Am J Vet Res 2002; 63:91–94.
-
15.
Sessions JKReynolds LRBudsberg SC. In vivo effects of carprofen, deracoxib, and etodolac on prostanoid production in blood, gastric mucosa, and synovial fluid in dogs with chronic osteoarthritis. Am J Vet Res 2005; 66:812–817.
-
16.
King JNRudaz CBorer L, et al. In vitro and ex vivo inhibition of canine cyclooxygenase isoforms by robenacoxib: a comparative study. Res Vet Sci 2010; 88:497–506.
-
17.
Kendall PTBlaza SESmith PM. Comparative digestible energy requirements of adult Beagles and domestic cats for body weight maintenance. J Nutr 1983; 113:1946–1955.
-
18.
Papich MG. Table of common drugs: approximate dosages. In: Kirk RWBonagura JD, eds. Kirk's current veterinary therapy XIV. St Louis: Saunders Elsevier, 2009:1306–1336.
-
19.
Brown SAFinco DRBrown CA, et al. Evaluation of the effects of inhibition of angiotensin converting enzyme with enalapril in dogs with induced chronic renal insufficiency. Am J Vet Res 2003; 64:321–327.
-
20.
Perazella MA. Drug-induced renal failure: update on new medications and unique mechanisms of nephrotoxicity. Am J Med Sci 2003; 325:349–362.
-
21.
Barkin RLBuvanendran A. Focus on the COX-1 and COX-2 agents: renal events of nonsteroidal and anti-inflammatory drugs-NSAIDs. Am J Ther 2004; 11:124–129.
-
22.
Khan KNVenturini CMBunch RT, et al. Interspecies differences in renal localization of cyclooxygenase isoforms: implications in nonsteroidal antiinflammatory drug-related nephrotoxicity. Toxicol Pathol 1998; 26:612–620.
-
23.
Jones CJBudsberg SC. Physiologic characteristics and clinical importance of the cyclooxygenase isoforms in dogs and cats. J Am Vet Med Assoc 2000; 217:721–729.
-
24.
Brater DCHarris CRedfern JS, et al. Renal effects of COX-2-selective inhibitors. Am J Nephrol 2001; 21:1–15.
-
25.
Harris RCZhang MZCheng HF. Cyclooxygenase-2 and the renal renin-angiotensin system. Acta Physiol Scand 2004; 181:543–547.
-
26.
Kramer BKKammerl MCKomhoff M. Renal cyclooxygenase-2 (COX-2). Physiological, pathophysiological, and clinical implications. Kidney Blood Press Res 2004; 27:43–62.
-
27.
Rossat JMaillard MNussberger J, et al. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther 1999; 66:76–84.
-
28.
Harris RC. The macula densa: recent developments. J Hypertens 1996; 14:815–822.
-
29.
Harris RCMcKanna JAAkai Y, et al. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 1994; 94:2504–2510.
Advertisement
Renal effects of carprofen and etodolac in euvolemic and volume-depleted dogs
Abstract
Objective—To determine the effects of carprofen and etodolac on renal function in euvolemic dogs and dogs with extracellular fluid volume depletion induced via administration of furosemide.
Animals—12 female Beagles.
Procedures—Dogs received a placebo, furosemide, carprofen, etodolac, furosemide and carprofen, and furosemide and etodolac. The order in which dogs received treatments was determined via a randomization procedure. Values of urine specific gravity, various plasma biochemical variables, glomerular filtration rate (GFR [urinary clearance of creatinine]), and renal plasma flow (urinary clearance of para-aminohippuric acid) were determined before and after 8 days of drug administration. A washout time of approximately 12 days was allowed between treatment periods.
Results—Administration of furosemide, furosemide and carprofen, and furosemide and etodolac caused changes in urine specific gravity and values of plasma biochemical variables. Administration of carprofen or etodolac alone did not have a significant effect on renal plasma flow or GFR. Concurrent administration of furosemide and carprofen or furosemide and etodolac caused a significant decrease in GFR. After 12-day washout periods, mean values of GFR were similar to values before drug administration for all treatments.
Conclusions and Clinical Relevance—Results indicated GFR decreased after 8 days of concurrent administration of furosemide and carprofen or furosemide and etodolac to dogs. Administration of preferential cyclooxygenase-2 inhibitors to dogs with extracellular fluid volume depletion or to dogs treated with diuretics may transiently impair renal function.
Contributor Notes
Powered by PubFactory